Alterations in DNA methylation strongly impact the activity of enhancers, which activate specific transcriptional profiles through recruitment of transcription factors that interact with the mediator complex31. To determine if enhancer activity is required for AREG and EREG expression in pancreatic cancer cells, we treated cells with JQ1, a BET bromo-domain inhibitor that is specific for BRD432. BRD4 interacts with the elongating factor P-TEFB in Pol II complexes to enhance transcription for both protein-coding and enhancer-derived noncoding RNAs33. We found that AREG and EREG expression markedly decreased with JQ1 treatment, thus indicating their transcriptional dependence on enhancer function (Fig. 2G–I).